Autopsy report · NCT05894447

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

“Insufficient funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Urothelial Carcinoma

Interventions

Naptumomab Estafenatox; Pembrolizumab; Obinutuzumab

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• PROactive Evaluation of Function to Avoid CardioToxicity
  “Insufficient funding/staff” (90% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (87% match in meaning)
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
  “Funding unavailable” (87% match in meaning)
• Hatha Yoga in Breast Cancer Survivors
  “Insufficient staff and funding” (87% match in meaning)
• Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
  “Inadequate funding” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.